Target Poor or Non Binder(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T85799 | Target Info | |||
| Target Name | Cyclin-dependent kinase 4 (CDK4) | ||||
| Synonyms |
PSK-J3; Cell division protein kinase 4
Click to Show/Hide
|
||||
| Target Type | Successful Target | ||||
| Gene Name | CDK4 | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Poor Binders of This Target (in total, 10 binders) | Download | Top | |||
|---|---|---|---|---|---|
| Compound Name |
R-roscovitine
Click to Show/Hide
|
Phase 2 | Compound Info | ||
| Synonyms |
Seliciclib; roscovitine; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; Roscovitine; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[1] | |||
| Compound Name |
Olomoucine
Click to Show/Hide
|
Terminated | Compound Info | ||
| Synonyms |
olomoucine; 101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[1] | |||
| Compound Name |
JNJ-10198409
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
JNJ-10198409; 627518-40-5; PDGFR Tyrosine Kinase Inhibitor IV; PDGF Receptor Tyrosine Kinase Inhibitor IV; CHEMBL120077; N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine; 3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; ZDNURMVOKAERHZ-UHFFFAOYSA-N; SCHEMBL3088170; GTPL6020; CTK8E8807; jnj10198409; DTXSID70430890; MolPort-009-019-131; HMS3650O03; HMS3229I11; ZINC13677843; BDBM50179207; AKOS030525202; RWJ 540973; CCG-206773; NCGC00343986-02; RT-014973; KB-274227; SR-01000946814
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[2] | |||
| Compound Name |
(3r)-1-{2-[4-(4-Acetylphenyl)piperazin-1-Yl]-2-Oxoethyl}-N-(3-Chloro-4-Hydroxyphenyl)pyrrolidine-3-Carboxamide
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL3356117; SCHEMBL7878839; BDBM50030881; Q27453793
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 50000 nM
|
[3] | |||
| Compound Name |
[(1S,3Ar,6E,9S,9aR,10R,11aS)-6-[[tert-butyl(2-hydroxyethyl)amino]methylidene]-1,5-dihydroxy-9-(methoxymethyl)-9a,11a-dimethyl-4,7-dioxo-2,3,3a,9,10,11-hexahydro-1H-indeno[4,5-h]isochromen-10-yl] acetate
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL271190
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 50000 nM
|
[4] | |||
| Compound Name |
1-(2-Amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl)-3-(tert-butyl)urea
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
PD089828; PD-089828; CHEMBL57366; 1-[2-amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 6-arylpyrido[2,3-d]pyrimidine deriv. 1; EGF/FGF/PDGF Receptor Tyrosine Kinase Inhibitor; BDBM3428; SCHEMBL8124128; AOB5747; EX-A4724; ZINC3815345; AS-16916; HY-112345; CS-0045270; J-002982; 1-[2-Amino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 50000 nM
|
[5] | |||
| Compound Name |
(1E,4S,4Ar,5R,6aS,7S,9aR)-5-(acetyloxy)-1-[[[3-(dimethylamino)propyl]methylamino]methylene]-4a,5,6,6a,7,8,9,9a-octahydro-cyclopenta[5,6]naphtho[1,2-c]pyran-2,10(1H,4H)-dione
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL410643; ZINC29134475; WAY-266176
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 50000 nM
|
[4] | |||
| Compound Name |
4,6 Bis anilino pyrimidine deriv. 9
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
BDBM7636; CHEMBL101779; 4-N-{4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl}-6-N-(4-methoxyphenyl)pyrimidine-4,6-diamine
Click to Show/Hide
|
||||
| Activity |
IC50 = 57000 nM
|
[6] | |||
| Compound Name |
Carbazole deriv. 22
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL67655; BDBM6960; 8-(3-Aminophenyl)-7H-benzo[c]carbazole-2-ol
Click to Show/Hide
|
||||
| Activity |
IC50 = 74500 nM
|
[7] | |||
| Compound Name |
2-(2,6-Dichloro-phenylamino)-7-(3-diethylamino-propenyl)-1,6-dimethyl-1,8-dihydro-imidazo[4,5-h]isoquinolin-9-one
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL281957; SCHEMBL6621670; BDBM50126732
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[8] | |||
| Click to Show/Hide the Information of All Poor Binders | |||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Selectivity and potency of cyclin-dependent kinase inhibitors. AAPS J. 2006 Mar 24;8(1):E204-21. | ||||
| REF 2 | A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. | ||||
| REF 3 | Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase. J Med Chem. 2014 Nov 13;57(21):8817-26. | ||||
| REF 4 | Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy. J Med Chem. 2008 Mar 13;51(5):1319-23. | ||||
| REF 5 | Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg Med Chem Lett. 1997 Sep 23;7(18):2415-20. | ||||
| REF 6 | Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2961-6. | ||||
| REF 7 | Identification of selective inhibitors of cyclin dependent kinase 4. Bioorg Med Chem Lett. 2001 Aug 20;11(16):2209-11. | ||||
| REF 8 | Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase. J Med Chem. 2003 Apr 10;46(8):1337-49. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.